[HTML][HTML] Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus
S Kang, YB Ahn, TK Oh, WY Lee, SW Chun… - Diabetes & Metabolism …, 2024 - e-dmj.org
Background This study investigated the real-world efficacy and safety of insulin
degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM) …
degludec/insulin aspart (IDegAsp) in Korean adults with type 2 diabetes mellitus (T2DM) …
Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins
JR Walt, J Loughran, S Fourlanos… - Internal Medicine …, 2024 - Wiley Online Library
Abstract Background and Aims IDegAsp (Ryzodeg 70/30), a unique premixed formulation of
long‐acting insulin degludec and rapid‐acting insulin aspart, is increasing in use …
long‐acting insulin degludec and rapid‐acting insulin aspart, is increasing in use …
[HTML][HTML] The Short-Term Cost-Effectiveness of a Fixed-Ratio Combination of Insulin Degludec and Aspart: A Cost of Control Analysis in Australia and India
JGU Romano, SJP Malkin, B Hunt - Value in Health Regional Issues, 2024 - Elsevier
Objectives The real-world ARISE study demonstrated initiation of fixed-ratio combination
insulin degludec and aspart (IDegAsp) led to improvements in people achieving key …
insulin degludec and aspart (IDegAsp) led to improvements in people achieving key …
[HTML][HTML] Improvement in Glycemic Indices and Point in Range by Addition or Switch to IDegAsp–Real-World Evidence
KG Seshadri, S Polisetti, S Tippisetty - Journal of Diabetology, 2024 - journals.lww.com
Aim and Objectives: This study aimed to evaluate the effectiveness of insulin
degludec/insulin aspart (IDegAsp) in uncontrolled type 2 diabetes mellitus (T2DM) patients …
degludec/insulin aspart (IDegAsp) in uncontrolled type 2 diabetes mellitus (T2DM) patients …
[HTML][HTML] Practical guide in using insulin degludec/insulin aspart: A multidisciplinary approach in Malaysia
SP Chan, M Mumtaz, J Ratnasingam… - … Family Physician: the …, 2023 - ncbi.nlm.nih.gov
Insulin degludec/insulin aspart (IDegAsp) co-formulation provides both basal and mealtime
glycaemic control in a single injection. The glucose level-lowering efficacy of IDegAsp is …
glycaemic control in a single injection. The glucose level-lowering efficacy of IDegAsp is …
[HTML][HTML] Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults With Type 2 Diabetes in the Philippines: Results from a Prospective, Non-interventional …
N Nicodemus Jr, N Ang-Golangco… - Journal of the …, 2024 - asean-endocrinejournal.org
Objectives. Blood glucose levels of the majority of Filipino patients with type 2 diabetes
(T2D) remain uncontrolled. Insulin degludec/insulin aspart (IDegAsp) is a fixed‑ratio co …
(T2D) remain uncontrolled. Insulin degludec/insulin aspart (IDegAsp) is a fixed‑ratio co …
[HTML][HTML] Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real …
M Mohamed, SC Lim, M Mumtaz, S Uppal… - Journal of the ASEAN …, 2023 - ncbi.nlm.nih.gov
Objectives Insulin degludec (IDeg)/insulin aspart (IAsp; IDegAsp) is a co-formulation of 70%
IDeg and 30% IAsp. According to several randomized controlled trials, IDegAsp is effective …
IDeg and 30% IAsp. According to several randomized controlled trials, IDegAsp is effective …
U kogo i dlaczego warto zastosować insulinę dwuanalogową aspart+ degludec?
M Dąbrowski - Medycyna Faktów, 2023 - journalsmededu.pl
Ostatnie lata przyniosły istotne zmiany paradygmatu terapii cukrzycy typu 2. Po ogłoszeniu
wyników pierwszych i kolejnych badań bezpieczeństwa sercowo-naczyniowego leków …
wyników pierwszych i kolejnych badań bezpieczeństwa sercowo-naczyniowego leków …
[PDF][PDF] Hypoglycemia in Type 2 Diabetes Patients Substituted with Insulin Degludec Aspart from Premixed Insulin Therapy: A Quasi Experimental Study
KM Malik, S Zafar, S Ali, M Noor, N Ishaq - pafmj.org
ABSTRACT Objective: To determine whether Insulin Degludec Aspart is associated with a
reduced risk of hypoglycemia as compared to premixed Insulin aspart therapy in type-2 …
reduced risk of hypoglycemia as compared to premixed Insulin aspart therapy in type-2 …
СТАРТ ТЕРАПИИ САХАРНОГО ДИАБЕТА С КОМБИНАЦИИ ИНСУЛИНА ДЕГЛУДЕК И ИНСУЛИНА АСПАРТ ИЛИ ПЕРЕВОД НА НЕЕ С ДРУГИХ РЕЖИМОВ У …
АМ МКРТУМЯН - ЭФФЕКТИВНАЯ ФАРМАКОТЕРАПИЯ Учредители …, 2022 - elibrary.ru
Несмотря на то что сахарный диабет 2 типа принято считать инсулиннезависимым
диабетом, весьма часто приходится прибегать к инсулинотерапии с целью …
диабетом, весьма часто приходится прибегать к инсулинотерапии с целью …